Apimeds Pharmaceuticals US Inc (APUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4 | 0 | 0 | 0 | 410 |
| Other current assets | 0 | 0 | 0 | 0 | 12 |
| TOTAL | $13 | $0 | $0 | $0 | $422 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $13 | $0 | $0 | $0 | $422 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 668 | 0 | 0 | 0 | 54 |
| Accrued Expenses | 107 | 0 | 0 | 0 | 69 |
| TOTAL | $1,024 | $0 | $0 | $0 | $123 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 347 | 0 | 0 | 0 | 267 |
| TOTAL | $347 | $N/A | $N/A | $N/A | $267 |
| Total Liabilities | $1,371 | $0 | $0 | $0 | $390 |
| Shareholders' Equity | |||||
| Common Shares | 79 | 0 | 0 | 0 | 79 |
| Retained earnings | -4,392 | 0 | 0 | 0 | -3,002 |
| TOTAL | $-1,358 | $0 | $0 | $0 | $32 |
| Total Liabilities And Equity | $13 | $0 | $0 | $0 | $422 |